1-3 of 3
Thomas Van Blarcom
Close
Save search
Sort by
Journal Articles

Investigation of Allocar T TM Targeting CD70 As a Potential Therapy for an Array of Hematological Malignancies

Free
Siler Panowski, PhD, Surabhi Srinivasan, MS, Thomas Van Blarcom, PhD, Cesar Sommer, PhD, Hsin-Yuan Cheng, PhD, Thomas Pertel, PhD, Marianne A Santaguida, PhD, Roman Galetto, PhD, Alan Dunlop, BSc, MSc, Reuben Benjamin, MD, Barbra Sasu, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5157.
https://doi.org/10.1182/blood-2019-128808
Published: 2019
Journal Articles

Preclinical Evaluation of ALLO-819, an Allogeneic CAR T Cell Therapy Targeting FLT3 for the Treatment of Acute Myeloid Leukemia

Free
Cesar Sommer, PhD, Hsin-Yuan Cheng, PhD, Yik Andy Yeung, PhD, Duy Nguyen, Janette Sutton, Zea Melton, Julien Valton, PhD, Kris Poulsen, Ivana Djuretic, PhD, Thomas Van Blarcom, PhD, Javier Chaparro-Riggers, PhD, Barbra Sasu, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3921.
https://doi.org/10.1182/blood-2019-129025
Published: 2019
Journal Articles

ALLO-715, an Allogeneic BCMA CAR T Therapy Possessing an Off-Switch for the Treatment of Multiple Myeloma

Free
Cesar Sommer, PhD, Bijan Boldajipour, PhD, Julien Valton, PhD, Roman Galetto, PhD, Trevor Bentley, Janette Sutton, Yajin Ni, PhD, Mark Leonard, PhD, Thomas Van Blarcom, PhD, Julianne Smith, PhD, Javier Chaparro-Riggers, PhD, Barbra Sasu, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 591.
https://doi.org/10.1182/blood-2018-99-119227
Published: 2018